title: [Retinal vein occlusion: Therapy of retinal vein occlusion].
abstract: Treatment of retinal vein occlusion can be systemic or local. Therapeutic strategies include improved blood supply, treatment of the vision-reducing macular edema by intravitreal injection of inhibitors of vascular endothelial growth factors (VEGF) or corticosteroids and laser photocoagulation for neovascular complications. As long as head-to-head studies comparing steroids and VEGF inhibitors have not been published, none of the available intravitreally injected substances can be given priority. Well-known side effects of intravitreal steroids are cataract formation and ocular hypertension whereas VEGF inhibitors need to be frequently injected. Although therapy for retinal vein occlusion is protracted, initial long-term data indicate that treatment can be terminated in at least half of the patients . Finally, a treatment recommendation according to the current state of data is presented.
authors.affiliation: Universitäts-Augenklinik Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland, nicolas.feltgen@med.uni-goettingen.de.
authors.forename: N
authors.initials: N
authors.lastname: Feltgen
authors.forename: A
authors.initials: A
authors.lastname: Pielen
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D058449:Intravitreal Injections; D008028:Light Coagulation / Q000379:methods*; D012170:Retinal Vein Occlusion / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A